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Abstract
Background—An inverted region on chromosome 17 has been previously linked to many Pick
complex diseases. Due to the inversion, an exact causal locus has been difficult to identify, but the
microtubule-associated protein tau gene is a likely candidate gene for its involvement in these
diseases with tau inclusion.




Participants—A total of 231 samples were genotyped from an unrelated white population of
patients with progressive supranuclear palsy (PSP), corticobasal degeneration (CBD),
frontotemporal dementia, and frontotemporal dementia with amyotrophy. Unaffected individuals
from the same population were used as controls.
Main Outcome Measures—The results from an inverted region of chromosome 17 that contains
the MAPT gene. Genotypes of cases and controls were compared using a Fisher exact test on a marker-
by-marker basis. Haplotypes were determined by visually inspecting genotypes.
Results—Comparing any particular disease and controls, the association was constant across the
inverted chromosome segment. Significant associations were seen for PSP and PSP combined with
CBD. Of the 2 haplotypes seen in the region, H1 was overrepresented in PSP and CBD cases
compared with controls.
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Conclusions—As expected, the markers are highly correlated and the association is seen across
the entire region, which makes it difficult to narrow down a disease-causing variant or even a possible
candidate gene. However, considering the pathologic abnormalities of these diseases and the
involvement of tau mutations seen in familial forms, the MAPT gene represents the most likely cause
driving the association.
Pick complex refers to a spectrum of diseases with a variety of overlapping clinical and
pathologic features due to a related genetic etiology. A common, although not ubiquitous,
overlapping feature of these diseases is the presence of tau inclusions. Thus, the genetic and
brain histochemical features of the microtubule-associated protein tau gene (MAPT) (OMIM
157140) provide a compelling reason for thinking that patients with these clinically and
pathologically diverse findings should be thought of as a contiguous group. These diseases are
characterized clinically by cognitive, behavioral, and movement defects. This study focused
on 4 diseases in the spectrum in which tau histochemical and genetic features are believed to
be critical: progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and
frontotemporal dementia (FTD) with or without amyotrophy.
The clinical signs and symptoms observed in patients with these diseases are correlated with
the anatomical distribution of neuronal loss, which can be variable. There are several patterns
of inclusions of insoluble proteins in affected individuals, but there is limited correlation
between inclusion type and clinical symptoms. Pick complex diseases can be accompanied by
tau inclusions, ubiquitin inclusions, or no inclusions at all.1 Pick complex diseases that contain
tau inclusions are collectively referred to as tauopathies.
Many families with inherited tauopathies have been linked to the same genomic region and,
thus, collectively, these families are said to be affected with FTD and parkinsonism linked to
chromosome 17 (FTDP-17).2 MAPT was considered to be a likely candidate gene in this region
for its involvement in FTD with tau inclusions and, subsequently, many MAPT mutations have
been identified in affected individuals. Tau mutations have been found to affect the level of
translated protein or alternative RNA splicing, which may upset the interaction between tau
and microtubules, allowing unbound and abnormally phosphorylated tau to polymerize into
inclusions.3 Different tau mutations alter biochemical properties of the gene product, but these
mutations do not necessarily predict the exact clinical nature of the disease. The same mutation
in affected individuals, even in the same family, may result in a different age at onset,
combination of symptoms, and clinical diagnosis.4 The variable morphologic features of
accumulated tau proteins could be explained by the wide range of mutations that have been
found in these diseases. In various tauopathies, the inclusions may differ based on the ratios
of particular isoforms and the physical location of accumulation. At least 40 MAPT mutations
have been identified in patients with FTD and related diseases.5 Tau inclusions, usually without
MAPT mutations, are part of the pathologic definition of CBD and PSP, whereas cases of FTD
are often seen without tau mutations or tau inclusions. Another set of cases with FTDP-17 that
contain ubiquitin inclusions, but no tau inclusions, was linked to the same region on
chromosome 17.6 Further gene resequencing of this set of cases led to the discovery of
mutations in the progranulin gene from this region; these mutations are responsible for many
cases of FTDP-17.6
In its natural state, MAPT works to stabilize microtubule formation and regulate transport along
microtu-bules.4 Dysfunctional tau proteins can interrupt axonal transport by reducing the cell’s
ability to control microtubule formation, ultimately leading to neuron dysfunction and death.
2 Normally, the tau protein is located in axons but, in diseased cells, it relocates to the cell
body and forms insoluble hyperphosphorylized fibrillary inclusions.1 This
hyperphosphorylation of tau may lead to a loss of microtubule affinity and a resistance to
proteases, leading to aggregation.7 Six major isoforms are produced in the adult human brain
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through the alternative splicing of exons 2, 3, and 10.4 The 6 isoforms can be divided into 2
groups, depending on the number of microtubule-binding domains. Alternative splicing of
exon 10 leads to 4-repeat (4R) or 3-repeat (3R) binding domains.4 The number of binding
domains affects the binding of tau to tubulin; 4R tau binds stronger and assembles more
efficiently than 3R tau.4 A reduction in binding efficiency may increase the amount of unbound
tau in the neuron, leading to aggregation, although increased binding may have an equally
damaging effect.4 An accumulation of unbound tau may result if any isoform fails to function,
creating insoluble inclusions.2 Inclusions found in affected individuals may contain all 6
isoforms in equal amounts or different ratios of selected isoforms. Many mutations disrupt the
splicing of exon 10, leading to unequal 3R and 4R ratios. Tau deposits in PSP and CBD are
predominantly 4R, whereas deposits in FTD contain equal levels of 4R and 3R.1
The region containing the MAPT gene has been shown to be genetically complex owing to an
inversion commonly found in white populations. Three highly homologous low-copy repeats
(LCRs) flank the region.8 The 2 LCRs telomeric of MAPT, LCRs B and C, are inverted relative
to the centromeric LCR A.8 Low-copy repeats A and B flank the MAPT haplotype, suggesting
that the inversion was caused by nonallelic homologous recombination.8 Figure 1 shows the
structure of MAPT in relation to these LCRs. Extensive genotyping across the interval identified
2 haplotypes in almost complete disequilibrium.9 These haplotypes are commonly referred to
as the H1 haplotype and H2 haplotype. Recombination in the inverted segment between carriers
of the H1 and H2 haplotypes would result in a Robertsonian translocation. The high degree of
disequilibrium in this region suggests that recombination has been suppressed or that there was
a selection against recombinant chromosomes before the inversion became established in the
white population.10 A study11 of tau expression in patients with Alzheimer disease found that
1 variant of the H1 haplotype led to an increase in overall tau levels and specifically in 4R tau
levels, creating an imbalance of isoforms. Similar changes in expression could be found in
these diseases.
There is a locus in or near the MAPT gene that affects susceptibility to PSP and CBD. Conrad
et al7 established that common variations in the MAPT gene affect susceptibility to PSP. They
reported that the A0 allele of a di-nucleotide repeat marker located in intron 9 of MAPT is
observed in 57% of control chromosomes compared with 95.5% of PSP cases.7 The A0 allele
was also shown to be overrepresented in CBD chromosomes.12 Other tauopathies have a less
certain association with MAPT region polymorphisms.7 The A0 allele is not believed to be
biologically relevant to the disease process but is instead in linkage disequilibrium with some
other polymorphism.7 The A0 allele is inherited with the H1 haplotype, so it is not surprising
that the H1 haplotype is also overrepresented in PSP cases.10 It is uncertain whether the
increased risk of PSP and CBD is associated with a specific common variation of the haplotype
or with a rare mutation found on some chromosomes with the H1 haplotype.7
Despite the varied clinical features used to categorize the different diseases, there is overlap,
suggesting that there could be a shared underlying biochemical abnormality resulting from the
altered expression of tau.12 To explore this possibility, we performed a high-density
association scan looking for markers that may confer susceptibility to several different
tauopathies. In this article, we focus on the markers contained in the region including and
surrounding tau. Using the present data, and genotypes imputed using HapMap, it was shown
that a significant association exists across the entire inverted interval on chromosome 17 for
PSP and CBD cases.
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SAMPLE COLLECTION AND PREPARATION
The included samples were collected by the Memory and Aging Center at the University of
California, San Francisco, or by one of us (K.C.W.). Cases of PSP, CBD, FTD, and FTD with
amyotrophy were collected from an unrelated white population. Cases of FTD met the Neary
criteria, and cases of PSP met the Litvan criteria. Although all the cases were clinically
confirmed, only 46 had pathologic confirmation of disease. None of the cases have known tau
or progranulin mutations. Unaffected individuals from the same population were used as
controls. DNA was isolated from whole blood using the Puregene kit (Gentra Systems,
Minneapolis, Minnesota). The number of patients used for each diagnosis in this study are as
follows: FTD, 56 (32 men and 24 women); PSP, 36 (20 men and 16 women); CBD, 22 (9 men
and 13 women); amyotrophic lateral sclerosis, 18 (11 men and 7 women); and controls, 98 (42
men and 56 women). The mean age was 73 years for controls and 67 years for cases, with an
average age at onset of 60 years. All the participants provided informed consent as approved
by the University of California, San Francisco, and The University of North Carolina at Chapel
Hill human subjects institutional review boards.
GENOTYPING
Genotyping was performed using the GeneChip 500K Affymetrix SNP arrays using the
protocol provided by Affymetrix (Affymetrix, Inc, Santa Clara, California). The BRLMM
algorithm was used to make genotyping calls. Acceptable genotypes had a confidence score
of less than 0.5. Any call that did not meet this threshold was removed from further analysis.
ANALYSIS
The genotypes of cases vs controls were compared using a Fisher exact test to determine
whether the allele frequency in the cases was significantly different from the controls. Markers
that were considered to be out of Hardy-Weinberg equilibrium were excluded from analysis.
There was no population stratification detected when tested using EIGENSTRAT software
(Harvard Medical School, Boston, Massachusetts). Genotype calls made using the BRLMM
algorithm were used to infer the remaining known HapMap markers in the area based on
correlation using the program IMPUTE from the Chiamo suite (Chiamo Genetics Software
Suite, University of Oxford, Oxford, United Kingdom). Imputed genotypes were considered
acceptable at a posterior probability greater than 0.8, and markers were included in association
tests if the call rate was greater than 80%.
RESULTS
Genomewide, the mean sample call rate was 95%, and the mean single nucleotide
polymorphism (SNP) call rate was 92% on the Affymetrix 500K platform. Less than 1% of
SNPs were out of Hardy-Weinberg equilibrium, and 1.5% of SNPs were monomorphic.
From the 326 SNPs typed in the MAPT region ranging from approximately 40.4 to 42.5 Mb
on chromosome 17, we attempted to impute an additional 4845 Hap-Map SNPs. After
eliminating imputed SNPs with a posterior probability lower than 0.8, 1477 SNPs remained.
Of these SNPs, 60 were monomorphic and 68 were not in Hardy-Weinberg equilibrium. Any
marker with a sample call rate less than 80% was removed. Genotypes for 1169 genotyped and
imputed SNPs were used to explore the region near the MAPT gene for allelic association with
PSP, CBD, FTD, and FTD with amyotrophy.
Figure 2A shows a plot of the probability that the cases and controls have equivalent genotype
frequencies for each of the typed or imputed SNPs that met the inclusion criteria for each of
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the disease classification models tested. All of the significant associations observed are within
the boundaries of the chromosomal inversion that distinguish the H1 and H2 haplotypes.
Although there are some exceptions, most markers across the inversion for any given
comparison fall within a constant range of probabilities across the interval. The most striking
associations observed are for PSP alone or combined with CBD vs controls across the entire
region of the chromosomal inversion. Rarely, a marker from other comparisons will reach a
nominally significant association, but these events are rare and are not constant across the
inverted interval. Inspection of the raw allele-specific hybridization intensity for these markers
does not robustly distinguish between genotype clusters and are not considered to be significant
associations. The region where allelic association is detected clearly defines the inversion
interval boundaries. Figure 2B shows the genotypes for all samples across the region of interest
in the following order: control, FTD, FTD with amyotrophy, CBD, and PSP. Each row
represents an individual, and each column represents a marker. Known genes are indicated as
lines above the genotypes. The samples were sorted based on diagnosis and haplotype
similarity. Two distinct haplotypes can be identified in this figure consistent with previous
designation of the H1 and H2 haplotypes.
Table 1 provides the counts for the 3 haplotype combinations (H1/H1, H1/H2, and H2/H2) for
each category of diagnosis. Very few heterozygous haplotypes, and no homozygous H2
haplotypes, were seen in either PSP or CBD. Compared with controls, using a Fisher exact
test, only PSP and PSP combined with CBD were significantly different. This confirms that
the H1 haplotype is overrepresented in PSP and CBD cases compared with controls and that
FTD and FTD with amyotrophy have H1 levels in the same proportion as controls (Table 2).
COMMENT
The association found in these tauopathies across this interval on chromosome 17 further
supports the theory that 1 or more loci in this region are affecting susceptibility specifically to
PSP and CBD. Because the markers are highly correlated and the association is seen across
the whole region, it is difficult to narrow down a disease-causing variant or even a possible
candidate gene. However, considering the pathologic features of these diseases and the
involvement of tau mutations seen in familial forms, the MAPT gene represents the most likely
cause driving the association.
Although all of the diseases in this study are tauopathies, not all of the diseases were highly
associated with this region. The hypothesis leading to this study was that similar diseases are
caused by mutations in genes controlled by similar biochemical pathways. So, although the
mutation causing any particular presentation of 1 of these diseases may be located in different
genes, the pathologic outcome is the same. There were other significantly associated regions
in the genomewide scan that may be affecting susceptibility to the diseases that were not as
highly associated with the tau region. No association was seen between FTD samples and this
region, although cases with FTD can have tau inclusions, and mutations of the tau gene have
been found in affected families. The lack of association may be affected by the small sample
size and the heterogeneity of sporadic FTD. Most cases of FTD do not have tau mutations or
inclusion, but cases of PSP and CBD are almost always accompanied by tau inclusions.
The odds ratio was calculated to determine the risk associated with a particular haplotype.
Controls have a 7-fold greater odds (95% confidence interval, 2.08–25.36) of having an H2
haplotype, on 1 or both chromosomes, compared with PSP and a 4-fold greater odds (95%
confidence interval, 1.16–15.10) compared with CBD. When CBD and PSP are considered
together, the odds ratio is in the middle, with a value of 5.7 (95% confidence interval, 2.24–
14.62). This suggests that the H2 haplotype provides some protection from the PSP and CBD
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diseases. This proposed protective allele is considered to be significant for PSP, CBD, and PSP
combined with CBD because none of the confidence intervals are less than 1.
Imputation filled in missing genotypes and genotypes for markers not included in the GeneChip
500K Affymetrix sets. This gave a fuller picture of the association in the region. Imputation
methods are useful for association studies because they combine information from genotyped
markers with existing data sets, such as HapMap. Testing a larger number of markers across
the genome provides a finer grid for association. However, in an area of high linkage
disequilibrium, as in the chromosome 17 inversion, the true disease-causing variant cannot be
distinguished from the surrounding markers even with the extra imputed genotypes. Imputation
added little to the association due to the strong linkage disequilibrium in the region that was
implicated. The regions flanking this inversion are much more thoroughly evaluated, and there
is little reason to investigate these flanking regions further. Filtering the data for call rate and
posterior probability removed noise and most false-positives that were detected using unfiltered
data. The genotype calling software used to impute genotypes resulted in more stringent and
reliable calls.
The results of this association study provide strong evidence that a susceptibility locus in the
MAPT gene region is related to certain Pick complex diseases, but the high degree of linkage
disequilibrium in the region makes it difficult to draw conclusions about the exact location of
the locus. To our knowledge, previous studies have reported results from candidate gene studies
focusing on the tau gene. We instead looked at the whole genome and found an association
with the entire inversion region, with no evidence that any part of the region is more important
than any other. The genotypes are constant across the inversion due to the high level of linkage
disequilibrium but, outside the inversion, they become highly variable, with no identifiable
pattern. This is also supported by the constant level of association that drops off at the
boundaries of the inversion. The inversion is likely a recent event because it is found only in
white populations. Although a specific cause cannot be determined, something in the inversion
is likely affecting expression of the tau gene and, ultimately, disease status. The inversion, or,
more specifically, the H2 haplotype, seems to offer some protection against PSP and CBD.
Acknowledgements
Funding/Support: This work was supported in part by the Schiller family, which has an endowed professorship at
The University of North Carolina at Chapel Hill for research into the cause and cure of PSP; grant RO1NS36733 from
the National Institute of Neurological Disorders and Stroke (Dr Wilhelmsen); the California State Alzheimer’s Disease
and Related Disorders Fund (Drs Wilhelmsen and Miller); The Amyotrophic Lateral Sclerosis Foundation (Dr
Wilhelmsen); The French Foundation (Dr Wilhelmsen), program project grant PO1 AG19724 from the National
Institute on Aging (Drs Miller and Wilhelmsen); and grant MO1RROOO79 from the National Center for Research
Resources (General Clinical Research Center at the University of California, San Francisco).
References
1. Williams DR. Tauopathies: classification and clinical update on neurodegenerative diseases associated
with microtubule-associated protein tau [review]. Intern Med J 2006;36(10):652–660. [PubMed:
16958643]
2. Neary D, Snowden J, Mann D. Frontotemporal dementia [review]. Lancet Neurol 2005;4(11):771–
780. [PubMed: 16239184]
3. Kertesz A. Pick complex: an integrative approach to frontotemporal dementia: primary progressive
aphasia, corticobasal degeneration, and progressive supra-nuclear palsy [review]. Neurologist 2003;9
(6):311–317. [PubMed: 14629785]
4. Rademakers R, Cruts M, van Broeckhoven C. The role of tau (MAPT) in frontotemporal dementia and
related tauopathies [review]. Hum Mutat 2004;24(4):277–295. [PubMed: 15365985]
Webb et al. Page 6













5. Rademakers R, Melquist S, Cruts M, et al. High-density SNP haplotyping suggests altered regulation
of tau gene expression in progressive supranuclear palsy. Hum Mol Genet 2005;14(21):3281–3292.
[PubMed: 16195395]
6. Pittman AM, Fung HC, de Silva R. Untangling the tau gene association with neurodegenerative
disorders [review]. Hum Mol Genet 2006;15(spec No 2):R188–R195. [PubMed: 16987883]
7. Conrad C, Andreadis A, Trojanowski JQ, et al. Genetic evidence for the involvement of tau in
progressive supranuclear palsy. Ann Neurol 1997;41(2):277–281. [PubMed: 9029080]
8. Cruts M, Rademakers R, Gijselinck I, et al. Genomic architecture of human 17q21 linked to
frontotemporal dementia uncovers a highly homologous family of low-copy repeats in the tau region.
Hum Mol Genet 2005;14(13):1753–1762. [PubMed: 15888485]
9. Stefansson H, Helgason A, Thorleifsson G, et al. A common inversion under selection in Europeans.
Nat Genet 2005;37(2):129–137. [PubMed: 15654335]
10. Baker M, Litvan I, Houlden H, et al. Association of an extended haplotype in the tau gene with
progressive supranuclear palsy. Hum Mol Genet 1999;8(4):711–715. [PubMed: 10072441]
11. Myers AJ, Pittman AM, Zhao AS. The MAPT H1c risk haplotype is associated with increased
expression of tau and especially of 4 repeat containing transcripts. Neurobiol Dis 2007;25(3):561–
570. [PubMed: 17174556]
12. Josephs KA, Petersen RC, Knopman DS, et al. Clinicopathologic analysis of frontotemporal and
corticobasal degenerations and PSP. Neurology 2006;66(1):41–48. [PubMed: 16401843]
13. NIEHS SNPs Program. NIEHS Environmental Genome Project Web page. [Accessed September
2007]. http://egp.gs.washington.edu
Webb et al. Page 7














The structure of the tau gene, indicating the locations of the microtubule-binding domains
(asterisks) and the flanking low-copy repeats (LCRs).
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Association and haplotypes across the interval. A, A plot of the negative log of the P value
from the comparisons between cases and controls. Known genes are represented as lines at the
top of the figure. B, The genotypes for all samples across the region of interest. Each row
corresponds to a sample. The samples were sorted based on diagnosis and haplotype similarity.
Samples with mostly blue, or major, alleles have the H1 haplotype, and samples with mostly
yellow, or minor, alleles have the H2 haplotype. Samples with mostly red, or heterozygote,
alleles are H1/H2. CBD indicates corticobasal degeneration; FTD, frontotemporal dementia;
MND, motor neuron disease; and PSP, progressive supranuclear palsy. The figure was created
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using the National Institute of Environmental Health Sciences SNPs Visual Genotypes
program.13
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